

OncoTherapy Science, Inc.

September 4, 2015

The completion of patient enrollment in Phase II clinical study of the cancer-specific peptide vaccine S-588410 in bladder cancer conducted by Shionogi & Co., Ltd.

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, “OncoTherapy”) announces that the bladder cancer patient enrollment for Phase II clinical study using a mixture of five peptide vaccines, S-588410, which OncoTherapy out-licensed to Shionogi & Co., Ltd. (Head office: Chuo-ku, Osaka, President and CEO: Isao Teshirogi; hereinafter, “Shionogi”) has been completed.

This clinical study has been conducted by Shionogi in Japan as well as in Europe to evaluate the clinical efficacy of S-588410 for bladder cancer patients.